ClinicalTrials.gg
CompletedNCT03291821Updated Dec 29, 2020

DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore

An interventional study of human menopausal gonadotropin and GnRH antagonist in Infertility, Female, sponsored by IVI Madrid. Completed at 1 site in Spain. Open to female participants aged 35 Years to 42 Years. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by IVI Madrid · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
35 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 33 studies in Infertility, Female with a site in Spain — 8 open to participants now, 8 under way, none of them phase 3. Infertility, Female · Spain.

Enrollment
8th of 26
136 · median 94
Started
2017
with 4 others
No phase
16 of 33
6 open now
Registered
9th of 33
by date
Lead sponsor
3 of 33
IVI Madrid

Among the 33 studies in Infertility, Female with a site in Spain, this one is the 8th largest by enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2017, is one of 16 with no phase, and was the 9th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 134 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

8 of the 33 studies in Infertility, Female with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 89 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 78 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 35 Years to 42 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Infertility, Female with a site in Spain, or all of them as a file.
02

Study summary

Since preimplantation genetic testing (PGT) is being more frequently requested from patients as women pursue infertility treatments at an advanced age with a poorer prognosis, sometimes physicians are compelled to perform several stimulation cycles to obtain more eggs and, consequently, a greater number of biopsied embryos. Hence, the idea of carrying out this study arises as an attempt to optimize each menstrual cycle to the maximum.

It is believed that the double stimulation (DuoStim) protocol could be an alternative for this group of patients, allowing to obtain a larger number of oocytes in a shorter period, thus, increasing the number of biopsied embryos and possibly decreasing the interval to achieve a successful pregnancy.

The investigators aim to evaluate the potential usefulness of the DuoStim protocol for patients desiring to obtain oocytes as soon as possible. Using PGT, the investigators will compare the rate of euploid embryos per cycle in patients undergoing DuoStim protocol versus patients undergoing two conventional controlled ovarian hyperstimulation in consecutive cycles. Patients will include women with advanced age and poor response.

This is a unicentric, prospective, randomized, non-blind, parallel-group controlled phase IV clinical study. The investigators hypothesize that the rate of euploid embryos per cycle is similar in the DuoStim group compared to the group undergoing two conventional controlled ovarian hyperstimulation in consecutive cycles.

Furthermore the investigators will evaluate if there are differences regarding the number of total oocytes obtained, the number of mature oocytes, the number of biopsied blastocysts and the MitoScore index of the available euploid embryos.

Read the detailed description

Classically, the follicular development was thought to occur only during the follicular phase of the menstrual cycle. However, new data demonstrated several waves of cyclic development of the antral follicles within the same menstrual cycle. Some authors insist that follicles formed during the luteal phase may have a similar ovulation potential of those formed in the follicular phase, thus offering new possibilities for ovarian stimulation.

Due to the use of vitrification technique and the appearance of the gonadotropins, physicians have been allowed to innovate the protocols applied to controlled ovarian hyperstimulation and have been able to obtain more oocytes in a shorter period for patients requiring rapid intervention, such as oncologic patients. Because of the accumulated experience with these new approaches, some investigators have recently proposed a double stimulation (DuoStim) protocol. Evidence of the competence of oocytes obtained from the luteal phase have been recently defined and published. Also, it has not been related with an increased risk for congenital anomalies.

The DuoStim is a protocol consisting of two stimulations within the same menstrual cycle, one in the follicular phase starting in day 2 of the cycle and the other in the luteal phase starting 5 days after the first ovarian puncture. Trigger is always performed with GnRH agonist.

Additionally, patients demanding infertility treatments are increasingly older and the use of preimplantation genetic testing (PGT) allows for a finer embryo selection along with better reproductive outcomes. Currently, most of PGTs are carried out at the blastocysts stage, which improve the prognosis but, on the contrary, also oblige to frozen those embryos and perform a deferred transfer, lengthening the procedure.

Another innovative tool for a more accurate embryo selection which has been recently described is the MitoScore. The MitoScore is a mitochondrial biomarker index developed by Igenomix aiming to indicate the energetic status of the embryo. It intends to select those embryos with best implantation potential and, therefore, more likely to result in an ongoing pregnancy after an IVF treatment. It is calculated dividing the number of mitochondrial DNA copies by the amount of nuclear DNA. Although still controversial, it has been proved by some authors to increase success rates of implantation and ongoing pregnancies in IVF cycles and to diminish the number of multiple gestations.

Since PGT is being more frequently requested from patients as women pursue infertility treatments at an advanced age with a poorer prognosis, sometimes physicians are compelled to perform several stimulation cycles to obtain more eggs and, consequently, a greater number of biopsied embryos. Hence, the idea of carrying out this study arises as an attempt to optimize each menstrual cycle to the maximum.

It is believed that the DuoStim protocol could be an alternative for this group of patients, allowing to obtain a larger number of oocytes in a shorter period, thus, increasing the number of biopsied embryos and possibly decreasing the interval to achieve a successful pregnancy.

The investigators aim to evaluate the potential usefulness of the DuoStim protocol for patients desiring to obtain oocytes as soon as possible. Also, using PGT, the investigators will compare the rate of euploid embryos per cycle in patients undergoing DuoStim protocol versus patients undergoing two conventional controlled ovarian hyperstimulation in consecutive cycles. Patients will include women with advanced age and poor response.

This is a unicentric, prospective, randomized, non-blind, parallel-group controlled phase IV clinical study. The investigators hypothesize that the rate of euploid embryos per cycle is similar in the DuoStim group compared to the group undergoing two conventional controlled ovarian hyperstimulation in consecutive cycles.

Furthermore the investigators will evaluate if there are differences regarding the number of total oocytes obtained, the number of mature oocytes, the number of biopsied blastocysts and the MitoScore index of the available euploid embryos. These variables will be assessed and compared depending on whether the oocytes were obtained in the follicular phase or the luteal phase for the DuoStim group. Resulting data will be compared with those obtained from the conventional stimulation group. The period elapsed from the beginning of the ovarian stimulation until the embryo transfer will also be addressed.

Patients will call the clinic at the Cycle Programing Department to arrange a treatment. After a short period taking contraceptive pills, patients will be referred to a medical appointment. At the time of the first consultation the attending physician will randomize patients desiring to participate and meeting inclusion criteria, using a random allocation software commissioned by the department of informatics. There will be no blinding since this study is an open trial.

Participants have the right to withdraw from the study at any time and for any reason without any inconvenience for their future medical care. Withdrawal means that the subject does not want to receive any further treatment nor does the patient wish to continue participating in the study. Reasons for withdrawal from the study: patient desire, lack of collaboration, toxicity or adverse event affecting patient's safety, decision of the principal investigator whenever the interruption is in favor of the patient's interests, death, and violation or breach of the study protocol.

The trial will be terminated when all participants have completed an adequate follow-up period. It might also be interrupted before completion date due to security reasons, failure to meet expected recruitment deadlines or even if there are any risks concerning patient's safety or health. All participants discontinued from the trial will remain in the follow-up phase, except for those who withdraw their informed consent or die.

Entries made in the Clinical Research Data Capture Profile (CRD) must be in accordance with those contained in the source documents. Data will be exported from the institutional repository software platform which withholds patient´s medical records. Integrity and accuracy will be checked by at least one investigator assuring that both extracted information and all the required regulatory documents are appropriate. Study files and all source documents will be stored for the time needed.

Considering an euploid embryo rate per cycle of 20% for conventional stimulation and a difference between means of 10% (Conventional X DuoStim group), a sample size of 136 patients (68 per arm) was estimated to obtain a power of 80% with an alfa error of 5%. A loss rate of 5% was also considered to calculate the sample size.

Categorical variables will be assessed by the number of subjects as well as absolute and relative frequencies. Continuous variables will be assessed by the means, medians, standard deviations, 25th and 75th percentiles, minimum and maximum. For both categorical and continuous variables, a confidence interval of 95% will be considered. The exploratory analysis of data will allow to determine quality of the data and to detect any abnormality.

The means and proportions of the descriptive variables will be compared to verify if the randomization was correctly performed. Whenever the variables are normally distributed, it will be applied a parametric test such as chi-square test for categorical variables and a T-student test or ANOVA for continuous variables. If the distribution is not normal a non-parametric test such as a Mann-Whitney U or Wilcoxon test will be applied according to the characteristics of the variable.

If the investigators find statically significant differences for descriptive variables between the two groups, those variables will be included in a regression model to control their interference.

Additionally, linear or logistic regression models will be defined, depending on whether the outcome variable is quantitative or categorical, respectively. It will allow to adjust possible confounding factors that may potentially influence the results.

03

Conditions studied

  • Infertility, Female

Browse trials for

Keywords

  • DuoStim
  • MitoScore
  • Preimplantation genetic diagnosis
  • MII oocyte
04

Who can participate

Ages eligible
35 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ;
  • 35-42 years of age;
  • Patients from the IVI Madrid undergoing controlled ovarian hyperstimulation cycle including PGT analysis for infertility treatment;
  • 18-30 kg/m2;
  • Suspicion of suboptimal or poor response:

AMH \< 1.5 ng/mL; AFC \< 8; FSH > 10; Poor response in a previous cycle (defined as \< 6 oocytes).

Exclusion criteria

Exclusion Criteria:

  • Simultaneous participation in another clinical trial or in any other study that could result in a confounding factor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    DuoStim

    Two controlled ovarian stimulation within the same menstrual cycle using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.

    Drug: human menopausal gonadotropin · Drug: GnRH antagonist · Drug: GnRH analog · Procedure: Trophectoderm biopsy · Diagnostic Test: MitoScore · Procedure: Intracytoplasmic sperm injection · Procedure: Ovarian puncture · Diagnostic Test: Preimplantation genetic test · Procedure: Embryo transfer · Diagnostic Test: Pregnancy test · Procedure: Embryo freezing · Procedure: Embryo thawing

  • Active comparator
    Conventional Stimulation

    Two controlled ovarian stimulation in different menstrual cycles using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.

    Drug: human menopausal gonadotropin · Drug: GnRH antagonist · Drug: GnRH analog · Procedure: Trophectoderm biopsy · Diagnostic Test: MitoScore · Procedure: Intracytoplasmic sperm injection · Procedure: Ovarian puncture · Diagnostic Test: Preimplantation genetic test · Procedure: Embryo transfer · Diagnostic Test: Pregnancy test · Procedure: Embryo freezing · Procedure: Embryo thawing

Interventions

  • DrugMenotropinsStudies of MenotropinsMenotropins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    human menopausal gonadotropin subcutaneously

    Also known as: menopur, meriofert

  • DrugGonadotropin Releasing Hormone AntagonistStudies of Gonadotropin Releasing Hormone AntagonistGonadotropin Releasing Hormone Antagonist pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GnRH antagonist subcutaneously

    Also known as: orgalutran, cetrotide

  • DrugGonadotropin-releasing Hormone AnalogStudies of Gonadotropin-releasing Hormone AnalogGonadotropin-releasing Hormone Analog pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GnRH analog subcutaneously

    Also known as: decapeptyl

  • ProcedureTrophectoderm biopsy

    Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.

    Also known as: embryo biopsy, blastocyst biopsy

  • Diagnostic testMitoScore

    The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.

  • ProcedureIntracytoplasmic sperm injection

    ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.

    Also known as: ICSI

  • ProcedureOvarian puncture

    Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.

    Also known as: pick up, egg retrieval

  • Diagnostic testPreimplantation genetic test

    The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.

  • ProcedureEmbryo transfer

    Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus

  • Diagnostic testPregnancy test

    A pregnancy test is used to determine whether a woman is pregnant.

  • ProcedureEmbryo freezing

    Embryo freezing is a method for cryopreserving embryos.

    Also known as: embryo cryopreservation, embryo vitrification

  • ProcedureEmbryo thawing

    Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.

06

What researchers measure

Primary outcomes

  1. Rate of euploid embryos per cycle

    Rate of chromosomally normal embryos per cycle in the DuoStim group compared to the group undergoing two controlled ovarian hyperstimulation in consecutives cycles.

    Time frame: up to 9 months

Secondary outcomes

  1. Number of oocytes obtained

    Total number of oocytes obtained in both arms after ovarian puncture

    Time frame: up to 9 months

  2. Number of fertilized oocytes

    Number of fertilized oocytes in both arms after FIV/ICSI procedure

    Time frame: up to 9 months

  3. Number of biopsied blastocysts

    Number of biopsied blastocysts in both arms

    Time frame: up to 9 months

  4. MitoScore index of the euploid embryos

    Analysis of the MitoScore index of the euploid embryos obtained in both arms

    Time frame: up to 9 months

  5. Implantation rate

    Implantation rate of euploid embryos in both arms after single or double embryo transfer

    Time frame: up to 9 months

  6. Pregnancy rate

    Pregnancy rate of euploid embryos in both arms after single or double embryo transfer

    Time frame: up to 9 months

  7. Abortion rate

    Abortion rate presented by each arm after single or double embryo transfer

    Time frame: up to 9 months

  8. Time until embryo transfer

    Period elapsed from the beginning of the ovarian stimulation until the embryo transfer

    Time frame: up to 9 months

07

Study locations

1 site
  • IVI Madrid
    Madrid, 28035, Spain
08

References and documents

Publications

  • Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003 Jul;80(1):116-22. doi: 10.1016/s0015-0282(03)00544-2. PubMed 12849812 ↗
  • Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013 Dec;100(6):1673-80. doi: 10.1016/j.fertnstert.2013.07.1992. Epub 2013 Aug 26. PubMed 23987516 ↗
  • Cakmak H, Rosen MP. Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol. 2015 Jun;27(3):215-21. doi: 10.1097/GCO.0000000000000180. PubMed 25919235 ↗
  • Sonmezer M, Turkcuoglu I, Coskun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011 May;95(6):2125.e9-11. doi: 10.1016/j.fertnstert.2011.01.030. Epub 2011 Feb 3. PubMed 21292255 ↗
  • von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009 Oct;92(4):1360-1365. doi: 10.1016/j.fertnstert.2008.08.011. Epub 2008 Oct 18. PubMed 18930226 ↗
  • Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010 Aug;27(8):491-4. doi: 10.1007/s10815-010-9429-0. Epub 2010 May 9. PubMed 20455017 ↗
  • Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, Shoham Z. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online. 2014 Dec;29(6):684-91. doi: 10.1016/j.rbmo.2014.08.009. Epub 2014 Sep 6. PubMed 25444501 ↗
  • Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, Trabucco E, Venturella R, Vajta G, Rienzi L. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016 Jun;105(6):1488-1495.e1. doi: 10.1016/j.fertnstert.2016.03.002. Epub 2016 Mar 25. PubMed 27020168 ↗
  • Bentov Y, Esfandiari N, Gokturk A, Burstein E, Fainaru O, Casper RF. An ongoing pregnancy from two waves of follicles developing during a long follicular phase of the same cycle. Fertil Steril. 2010 Jun;94(1):350.e8-11. doi: 10.1016/j.fertnstert.2009.12.033. PubMed 20138269 ↗
  • Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014 Jan;101(1):105-11. doi: 10.1016/j.fertnstert.2013.09.007. Epub 2013 Oct 23. PubMed 24161646 ↗
  • Chen H, Wang Y, Lyu Q, Ai A, Fu Y, Tian H, Cai R, Hong Q, Chen Q, Shoham Z, Kuang Y. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril. 2015 May;103(5):1194-1201.e2. doi: 10.1016/j.fertnstert.2015.02.020. Epub 2015 Mar 23. PubMed 25813280 ↗
  • Diez-Juan A, Rubio C, Marin C, Martinez S, Al-Asmar N, Riboldi M, Diaz-Gimeno P, Valbuena D, Simon C. Mitochondrial DNA content as a viability score in human euploid embryos: less is better. Fertil Steril. 2015 Sep;104(3):534-41.e1. doi: 10.1016/j.fertnstert.2015.05.022. Epub 2015 Jun 11. PubMed 26051102 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Dec 2019, 24 months.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's 24 months is close to that.

Counting every sponsor, half of 157 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2017
First posted
Sep 25, 2017
StartActual
Dec 1, 2017
Primary completionActual
Dec 1, 2019
CompletionActual
Jun 1, 2020
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03291821
Lead sponsor
IVI Madrid
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Dec 1, 2017
Primary completion
Dec 1, 2019
Completion
Jun 1, 2020
Last update
Dec 29, 2020

Study contacts

Maria Cerrillo, M.D., Ph.D.
principal investigator · IVI Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Menotropins · Gonadotropin Releasing Hormone Antagonist · Gonadotropin-releasing Hormone Analog

Start the discussion